0000899243-18-009681.txt : 20180406
0000899243-18-009681.hdr.sgml : 20180406
20180406180114
ACCESSION NUMBER: 0000899243-18-009681
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180403
FILED AS OF DATE: 20180406
DATE AS OF CHANGE: 20180406
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: De Paolantonio Ernest Robert
CENTRAL INDEX KEY: 0001588538
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-31361
FILM NUMBER: 18744148
MAIL ADDRESS:
STREET 1: 4131 PARKLAKE AVENUE SUITE 225
CITY: RALEIGH
STATE: NC
ZIP: 27612
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BIODELIVERY SCIENCES INTERNATIONAL INC
CENTRAL INDEX KEY: 0001103021
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 352089858
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 4131 PARKLAKE AVENUE
STREET 2: SUITE 225
CITY: RALEIGH
STATE: NC
ZIP: 27612
BUSINESS PHONE: 919 582 9050
MAIL ADDRESS:
STREET 1: 4131 PARKLAKE AVENUE
STREET 2: SUITE 225
CITY: RALEIGH
STATE: NC
ZIP: 27612
FORMER COMPANY:
FORMER CONFORMED NAME: MAS ACQUISITION XXIII CORP
DATE OF NAME CHANGE: 20000111
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-04-03
0
0001103021
BIODELIVERY SCIENCES INTERNATIONAL INC
BDSI
0001588538
De Paolantonio Ernest Robert
C/O BIODELIVERY SCIENCES INTL, INC.,
4131 PARKLAKE AVE. SUITE 225
RALEIGH
NC
27612
0
1
0
0
CFO, Secretary and Treasurer
Common Stock
2018-04-03
4
A
0
1267
0.00
A
97731
D
Common Stock
2018-04-03
4
M
0
34391
0.00
A
132122
D
Common Stock
2018-04-03
4
M
0
30000
0.00
A
162122
D
Common Stock
2018-04-03
4
M
0
31667
0.00
A
193789
D
Common Stock
2018-04-03
4
M
0
27075
0.00
A
220864
D
Common Stock
2018-04-05
4
S
0
30900
2.12
D
189864
D
Common Stock
2018-04-06
4
S
0
33255
2.06
D
156709
D
Restricted Stock Units
0.00
2018-04-03
4
A
0
1267
0.00
D
2018-04-03
Common Stock
1267
0
D
Restricted Stock Units
0.00
2018-04-03
4
M
0
34391
0.00
D
2018-04-03
Common Stock
34391
0
D
Restricted Stock Units
0.00
2018-04-03
4
M
0
30000
0.00
D
2019-03-01
Common Stock
30000
30000
D
Restricted Stock Units
0.00
2018-04-03
4
M
0
31667
0.00
D
2020-02-06
Common Stock
31667
63333
D
Restricted Stock Units
0.00
2018-04-03
4
A
0
27075
0.00
D
2020-02-06
Common Stock
27075
0
D
The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units ("RSUs") granted to the Reporting Person under the Issuer's Long-Term Incentive Plan.
The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 23, 2015, pursuant to a grant under the Issuer's 2011 Equity Incentive Plan, as amended (the "EIP"). Upon vesting, each RSU entitles the Reporting Person to one share of the Issuer's common stock.
The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs that were granted to the Reporting Person on February 29, 2016, pursuant to a grant under the EIP. The remainder of the RSUs under this grant will vest on March 1, 2019.
The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 6, 2017 under the EIP. The remainder of the RSUs under this grant will vest in equal portions after the first open window upon the filing of the Company's Annual Report in March 2019 and March 2020.
The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the performance-based RSUs ("Performance RSUs") granted to the Reporting Person on February 6, 2017 under the EIP subject to certain performance measures. The remainder of the Performance RSUs under this grant will vest, in equal amounts, but subject to certain performance measures, after the first open window upon the filing of the Company's Annual Report in March 2019 and March 2020.
The shares of common stock were sold by the Reporting Person upon expiration of a pre-planned 10b5-1 trading plan and were sold to cover the Reporting Person's additional tax liability upon the vesting of the Reporting Person's RSUs.
On April 5, 2018, the Reporting Person sold an aggregate of 30,900 shares of the Issuer's Common Stock at a weighted average price of $2.12 per share. The highest sale price for the Common Stock was $2.15 per share and the lowest sale price was $2.08 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
On April 6, 2018, the Reporting Person sold an aggregate of 33,255 shares of the Issuer's Common Stock at a weighted average price of $2.06 per share. The highest sale price for the Common Stock was $2.15 per share and the lowest sale price was $2.00 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
/s/ Ernest R. De Paolantonio
2018-04-06